Characteristics of the Pathogen Causing vCJD
Experimental transmission of the disease is possible by injecting suspensions from the brains of TSE-infected and deceased animals or humans into laboratory animals. The incubation period depends on the infectious dose and the route of infection. The most effective route is intracerebral injection. One intracerebral infectious dose (ID50i.c.) is the dose which causes the disease in 50% of the animals inoculated by intracerebral injection. Higher doses are required for parenteral or oral infection while the incubation period using the same dose increases compared with intracerebral infection, depending on the route of infection (intracerebral < intravenous < intraperitoneal < subcutaneous < oral). Adaptation phenomena are observed in transmissions that cross the species barrier, leading to longer incubation periods or requiring higher infectious doses. The infectious agent has some unusual characteristics. It is insensitive to UV and gamma radiation and is very heat resistant. In purified preparations from scrapie-infected brains, the agent can be shown as fibrils in the electron microscope, which develop by aggregation of infectious prion proteins (PrP Sc ) ( fig. 1 ). Using polyacrylamide gel electrophoresis after cleavage with proteinase K, three protein bands are shown in such preparations which are located in the range of 27-30 kDa (PrP27-30). The three bands of the PrP27-30 show differently glycosylated forms of the protein ( fig. 2) [3] . Experimental data were collected to an increasing extent in the past few years indicating that the TSE pathogen is an infectious protein particle [4, 5] . Stanley Prusiner created the term prions (short for proteinaceous infectious particles) and called the diseases prion diseases [6] . According to the present definition, prions are transmissible pathogens which do not contain nucleic acid and consist exclusively of a protein PrP Sc (Sc = scrapie) with modified folding structure. In 2005, Brown and Cervenakova [7] suggested introducing the more unambiguous term of PrP TSE . Since this term, however, did not yet become common usage, we continue to use the abbreviation PrP Sc in this text. Normal cellular prion protein (PrP c ; encoded from the PRNP gene on chromosome 20 of humans) is converted to the protease-resistant PrP Sc by post-translational processes. This is characterised by a high portion of beta-sheet structures, i.e. PrP Sc has the same primary structures as cellular protease-sensitive PrP c , however, altered secondary and tertiary structures. PrP c is a glycoprotein, especially linked with the surface of nerve cells and cells of the immune system. The physiological function of PrP c has so far not been sufficiently understood. PrP c is the precondition for TSE development, for PrP c knock-out mice do not develop any symptoms following infection. Progression of infection and occurrence of symptoms are associated with accumulation of PrP Sc in the nerve tissue (brain) [8] .
Infection and Infectious Diseases
All previously known TSEs in humans and animals can be transmitted to experimental animals, both by intracerebral infection [9] [10] [11] [12] and frequently by oral administration, with cross-species infection requiring higher infectious doses in the first passage. For various TSEs in animals, it is assumed that oral uptake, e.g. of pathogen-containing food, was the main route of transmission (table 2) . The various forms of Creutzfeldt-Jakob disease are subdivided into spontaneous (or sporadic) CJD (sCJD), familial CJD (fCJD), iatrogenic CJD (iCJD) and variant CJD (vCJD) (table 1). Whereas the cause of sCJD is still unidentified, fCJD is inherited as an autosomal-dominant trait by mutations in the PRNP gene. Iatrogenic transmissions have occurred predominantly by dura mater preparations (e.g. transplantations) and human growth hormone (hGH) products prepared from cadaveric pituitary glands (table 3) . Results of previous investigations show that kuru and BSE/vCJD are acquired from food. Experimental investigations on the course of infection show that lymphatic cells or tissues play an important role in the transmission of the pathogen [13] . While the BSE and sCJD pathogens in the natural host are located mainly in the nerve tissue, PrP Sc and infectivity are also found in the lymphatic tissue, both in Scrapie-infected sheep and in vCJD patients, above all in follicular dendritic cells, tonsils, the spleen, and lymph nodes [13] (1 = 263K; 3 = ME7-H; 4 = 22A-H) and one hamster-adapted BSE strain (2 = BSE-H). After treatment with protease enzyme, the PrP proteins were separated using polyacrylamide gel and marked with a monoclonal antibody (3F4). The identification was performed by means of an enzyme-marked second antibody. The lower bands show the unglycosylated form, the medium band the monoglycosylated form, and the upper band the diglycosylated form of the prion protein.
affected, but that PrP Sc is also found -even if only in smaller amounts -in muscular tissue of experimentally infected animals. The same is true of patients who died of vCJD [14] [15] [16] .
sCJD
After occurrence of symptoms (table 4), the sCJD usually manifests itself as a rapidly progressing, normally neuropsychiatric disease, usually in persons over 60 years of age. First symptoms are frequently dementia and/or ataxia. Periodic sharp-wave complexes in the EEG are observed in the middle stage of the disease. Cerebrospinal fluid is normal regarding standard parameters. CJD can be distinguished from other neurodegenerative diseases by detection of the 14-3-3 proteins with a specificity of <90% [17] . Hyperintense basal ganglia can typically be detected in magnetic resonance imaging [18] . At least two of the following symptoms are used for clinical diagnosis of suspected CJD: myoclonias, visual or cerebellar signs of disease, pyramidal or extrapyramidal signs of disease and akinetic mutism [19] . The disease leads to death within a few months or in less than 2 years. The incidence of the disease has remained constant with 1-2 per 1 million inhabitants and per year over a period of 20 years [20] . There is neither a familial disposition, nor can exposure to infectious prion protein be seen. It is assumed that somatic mutations of the PRNP gene occur in cells which favour misfolding of the PrP c , or spontaneous refolding processes take place which lead to PrP Sc . In sCJD, as in other human TSEs, a pronounced association of the disease with homozygosis (methionin or valin) at codon 129 of the PRNP gene occurs, preferably in persons who are homozygous for methionin at this position (table 5).
Genetically Determined CJD
Approximately 10% of all cases of CJD are of genetic origin. Genetic tests have shown that the disease is inherited as an autosomal-dominant trait. The patients have at least one allele of a mutated PRNP gene. The medical history of a neurodegenerative disease in the family, however, is often unknown. GSS is also genetically determined with mutations in the PRNP gene (table 6) , predominantly with an association with homozygosis at codon 129 (met/met). Tests could show that the disease is transmissible to chimpanzees and other monkey species, as well as transgenic mice, using brain homogenates [12] . FFI is a very rare disease which is also associated with defined mutations in the PRNP gene (table 6 ). In addition, homozygous methionin is found at codon 129 of the PRNP in diseased persons. Transmission of the disease to transgenic mice gives evidence of its infectious character [6, 21] .
Kuru
Kuru was described in the 1950s as a disease which occurred in the Fore tribe on Papua New Guinea. Epidemiological studies provided evidence that above all the consumption of and possibly the rubbing in of brain tissue of deceased tribe members caused the transmission of the disease. Measures which started in the late 1950s to ban the consumption of brain resulted in a gradual decrease in new infections. Evidence of the transmissibility of the disease was given through experiments with transmission to chimpanzees [12, [22] [23] [24] .
iCJD
The clinical course of iatrogenically transmitted CJD infections by dura mater is comparable with that of sCJD. Besides The major clinical symptom of the recipients of such growth hormone is a subacute cerebral syndrome with only mild dementia. In the 1980s, production of hGH was changed over to products prepared by genetic engineering, thus eliminating growth hormone prepared from cadaveric pituitary glands as a source of infection. Other sources of infection in iatrogenic transmissions were identified as 3 cornea transplantations, and, in 3 cases, electrodes implanted in the brain (table 3 ). In the past few years, iatrogenic transmission through surgical instruments has been discussed extensively by expert commissions, and recommendations for the cleaning and sterilisation have been elaborated to minimise the risk of transmission through surgical instruments [25] [26] [27] [28] . Recommendations for the use and processing of such instruments have been elaborated which largely exclude the risk of a transmission.
vCJD
vCJD first occurred in humans in the UK around 1996, 10 years after the beginning of the BSE epidemic in cattle. Histological and biochemical tests pointed to characteristics of the pathogen (e.g. lesion patterns, PrP Sc protein patterns) comparable to those of BSE, which could further be confirmed by animal experiments [29] . These findings and the epidemiology of BSE indicated that persons became infected with vCJD by consuming food from cattle contaminated with the BSE pathogen. The aetiopathology of vCJD is a progressive neuropsychiatric disease. It progresses more slowly than sCJD. Its duration is as a rule a median period of 14 months. Clinical signs include early psychiatric symptoms (depression, anxiety, apathy, withdrawal, delusions), persisting painful dysaesthesia, ataxia, myoclonus, chorea or dystonia, and dementia.
Epidemiology
The incidence of CJD is 1-2 cases per 1 million inhabitants per annum worldwide. 85-90% of all CJD cases are so-called sCJD or iCJD cases which can be divided into 6 subtypes. Approximately 10% are genetically determined CJD. GSS and FFI are rare or very rare diseases [20] . No cases of diaplacental transmission have so far been reported. Iatrogenic transmissions of CJD (table 3) were reported. They were caused by hGH and gonadotropin isolated from cadaveric pituitary glands or by transplantation of dura mater and cornea as well as by electrodes applied intracerebrally which were insufficiently sterilised. The risk of transmission by hGH and dura mater was largely excluded by the introduction of suitable measures. Growth hormones have been prepared by genetic engineering since the mid 1980s, and dura mater was subjected to a specific processing procedure (1 mol/l NaOH, 24 h) which inactivates the pathogen. Polymorphism (methionin or valin) at position 129 of the amino acid sequence of the PrP may play a role both for the susceptibility to the disease and for the aetiopathology. It could be shown in various investigations that patients with CJD were frequently homozygous at this position (essentially met/met). While in the general population between 40 and 50% are heterozygous (met/val), the proportion of heterozygous persons drops to 10-15% in persons with TSE diseases (cf. [20, 35] . In the EU, registering all human TSE cases was started in 1993 in order to identify geographical distribution and outbreaks [20] . Retrospective examinations of tonsils and appendices in the UK, using more than 16,000 fixated tissue samples, of which 13,000 were evaluable, showed plaques of abnormal prion protein in 3 appendix samples in the immunohistochemistry [36] [37] [38] . To what extent these results provide proof for the prevalence of infection with vCJD in the UK is discussed controversially since these findings cannot be confirmed by further methods of examination and 2 of the 3 positive samples showed a previously unknown pattern for vCJD regarding morphology and distribution of the stained prion protein. 
Detection Methods and Their Significance
Up to now, there are no diagnostic procedures which unambiguously identify TSE in blood. A definitive confirmation of the diagnosis can only be performed by immunohistological examination of brain tissue. Prion protein in vCJD has shown to be also detectable in the peripheral lymphatic tissue, e.g. tonsils and appendix [29, [37] [38] [39] [40] [41] . Variant Creutzfeld-Jakob Disease 231 
Blood and Plasma Donors

Prevalence and Incidence in Donor Populations
Up to now, there are no sufficiently well-documented data on the prevalence of CJD cases among blood and plasma donors. It is assumed that the prevalence of CJD among blood donors is comparable with the prevalence in the general population (cf. 1.3). Extensive examinations on blood donation activities among the vCJD cases identified in the UK prove that up to now 15 persons who later developed vCJD were blood donors, and that a total of 55 preparations were produced from these donations [45, 46] .
Definition of Exclusion Criteria
According to the guidelines on blood group determination and blood transfusions (haemotherapy) (www. 
Donor Testing and Significance
So far, no systems exist for the testing of blood donors or blood donations for TSE.
Donor Interviews
The purpose of donor interviews is to clarify the exclusion criteria listed in 2.2. Above all, the aim is to identify whether relatives developed CJD or whether hGH was used to treat growth disorders (microsomia) (see the details on the use of hGH from pituitary glands). In addition, treatment with gonadotropin in hormone treatment (before 1993) should be identified. Interview questions on whether corneal transplantations took place are usually simple to answer, whereas the question of whether dura mater transplants were received can seldom be answered. Special importance is attached to the questions of time and duration of residence as well as medical treatment, especially surgery and transfusions, in the UK.
Donor Information and Counselling
Potential donors should be informed individually on the reasons given for donor exclusion.
Recipients
Prevalence and Incidence of Blood-Associated Infections and Infectious Diseases in Recipient Populations
The data on the prevalence and incidence of human TSE available up to now show that it is indicated to subdivide these diseases into two groups according to the risk of transmission by blood. There is up to now no evidence that there is a recognisable risk of transmission by blood or blood components from individuals with sCJD, fCJD or iCJD [25] . The measures taken to interview and exclude such donors, however, are justified as a precautionary measure in view of the fact that the disease always has a fatal outcome [47] . The situation is different for vCJD according to state-of-theart knowledge. In 2004, the first case of vCJD in a blood recipient in England was reported [46] . This individual (homozygous at codon 129 (met/met)) had received a transfusion 6.5 years before he developed the disease. The donor had devel- Arbeitskreis Blut oped vCJD 3.5 years after the identified donation and had died. The second case of evidence for a vCJD transmission concerned a person who died of aneurysm rupture and had previously not shown any signs of vCJD. Since all individuals in England who received blood or blood components originating from donors who developed subsequent vCJD had been identified [48] , the above-mentioned case was subjected to a post mortem examination and examined for vCJD-specific PrP Sc using immunohistological and biochemical methods. PrP Sc could be identified both in the brain and in the lymphatic tissue. This patient showed no neurological symptoms at the time of his death, and was heterozygous (met/val) for codon 129 of the PRNP gene [49] .
Immune Status (Resistance, Existing Immunity, Immune Response, Age, Exogenous Factors)
Previously available findings on the susceptibility and frequency of human TSE indicated that there is a genetic predisposition which is particularly located in the gene for PrP. For susceptibility, above all polymorphism at codon 129 of this gene plays an important part (table 5) . In this context, the genotype at codon 129 influences susceptibility and incubation periods. Methionin-homozygous persons develop the disease earlier and more frequently than heterozygous persons. For vCJD, evidence was found that so far all individuals who had developed vCJD were homozygous for met/met at codon 129. Whether or not individuals who are homozygous for valine (val/val) or heterozygous (met/val) also develop vCJD or have longer incubation periods is so far unknown [50] .
Severity and Course of the Disease
TSE diseases are always of fatal outcome. Data on the average duration of the disease are available for the different forms of the disease (table 6 ). For vCJD, there are only estimates of the incubation period so far. Such estimates refer to the time point of the risk of possible exposure to food contaminated with the BSE pathogen, with a high risk being assumed particularly with the period between 1980 and 1996. Here, too, the previously documented cases of possible transmission by blood components can only provide first indications of the incubation period (3-7 years or more) after infection by blood transfusion.
Therapy and Prophylaxis
There is so far no causal treatment. Treatments with quinacrine or pentosanpolysulphate are currently being developed [51] on the basis of results of animal experiments.
Transmissibility
Transmission of the TSE pathogen by social contacts is ruled out in humans. For human TSE pathogens, transmissions were above all observed via growth hormones and transplants (dura mater, cornea 
Frequency of Administration, Type and Amount of Blood Products
There are so far no results indicating whether frequent use of blood and plasma derivatives will cumulatively increase the risk of an infection with TSE pathogens. Epidemiological examinations of haemophiliacs did not point to a transmission by plasma products [54] . Several thousand recipients of potentially contaminated plasma products, in the manufacture of which donations of individuals who later developed vCJD had been included, have so far not developed any symptoms.
Blood Products
Infectious Load of the Starting Material and Test Methods
At present, no test methods are available to show the infection status of a donor or to identify the pathogen in blood and plasma donations. In the course of test development, decisions will also have to be made on the way retained and follow-up samples are to be collected and stored.
Methods for Removal and Inactivation of the Infectious Agent
Because of the stability of the TSE pathogen [55] , no methods have so far been available to inactivate the pathogen in blood and blood/plasma products. Since it could be shown that follicular dendritic cells and B lymphocytes play an essential role in establishing TSE [56] , leucocyte depletion was introduced in various countries, partly with the justification that this would reduce the risk of transmission of human TSE by blood components. Concurrently, quality was increased and immunological tolerability improved. Variant Creutzfeld-Jakob Disease 233 tion can reduce the titre of the TSE pathogen in erythrocyte concentrates by approximately 40% [57] . Leucocyte depletion is therefore considered as a step towards partial removal of cell-bound TSE pathogens which, however, does not exclude the risk of a transmission.
Feasibility and Validation of Procedures for Removal/ Inactivation of the Infectious Agent
In the past few years, extensive trials have also been performed to validate the various production steps in view of a reduction of the titre of the TSE pathogen in plasma products [58, 59] . For this purpose, tests were carried out both in plasma which was spiked with brain suspensions of infected animals or with fractions enriched with TSE pathogens, as well as in brain suspensions of humans who had died of vCJD, sCJD or GSS [60] . In addition, tests were carried out with the blood of infected animals [61] . Foster [62] has summarised the previous studies performed with endogenous TSE pathogens and exogenous infectious material. Altogether, a marked reduction in the titres of the TSE pathogen by between 10 4 and 10 7 is reached by fractionation, chromatography and filtration steps in the model systems [62] . High reduction rates have been observed in model systems for the removal of animal TSE pathogens by means of nanofiltration. However, the capacity of these filters to retain the pathogen very largely depends on the aggregation status of the pathogen material used in the experiment. In an experiment with highly dispersed pathogen material, infectivity passed even through the small porous 15 nm filter. Since the aggregation status of the vCJD pathogen is not known in the intermediate products during production of plasma proteins, the actual benefit from nanofiltration involves some uncertainty in view of vCJD safety. This also applies to the examination of the other production steps with spiked material. The conclusions that can be drawn from the experiments on the elimination of TSE pathogens from the blood of infected animals are above all limited by the low infection titres since only low reduction factors can be calculated.
Assessment
Transmission of TSE pathogens by blood and blood components or their derivatives could be shown in animal experiments. There is so far no evidence that sCJD, fCJD or iCJD can be transmitted by blood or blood components. In two cases in the UK, however, epidemiological investigations indicate that the pathogen of vCJD was transmitted by blood components. In principle, it can therefore not be ruled out that vCJD transmission by transfusion can occur in Germany, too. The measures so far taken in Germany and other countries for the reduction of the low risk of TSE caused by transfusions are based on assumptions concerning the prevalence of infections with human-pathogenic TSE and the probability of a transmission by blood and blood products. In this context, it is considered as an essential measure to exclude donors who stayed in the UK for more than 6 months between 1980 and 1996, received a transfusion or underwent surgery in that country later than early 1980. The high number of vCJD cases in the UK compared with other countries gives rise to the conclusion that, in keeping with state-of-the-art knowledge, the risk of infection by the consumption of BSE-contaminated food was increased in the UK between 1980 and 1996. Since the number of BSE-infected cattle in Germany was by two orders of magnitude smaller than in the UK, it can be assumed that exposure was accordingly smaller for the population.
Since no test will be available for TSE detection in human blood in the near future, donor selection is currently the only method of reducing the risk of TSE transmission. On the basis of the results obtained from experimental systems, leucocyte depletion can only remove part of the infectivity by reduction of white blood cells. To what extent this procedure reduces the risk of vCJD transmission remains open in view of the few transmissions that occurred to date and the low number of identified vCJD-infected donors. Methods must be established to remove TSE pathogens from cellular blood components and plasma for transfusion in order to reduce the risk of transmission by vCJD pathogens. The findings obtained up to now on the elimination of TSE pathogens in various production steps for the manufacture of plasma derivatives indicate that there is sufficiently high product safety regarding the risk of transmission by plasma derivatives. Since, however, only addition of preparations from TSEcontaining brains brings about titres sufficiently high for these experiments, discussions are held as to whether these preparations reflect the infectious agents contained in the blood. In the blood of infected animals only low titres are reached so that the actual capacity of the method to remove the pathogen cannot be demonstrated. The aim of developing better detection methods is to lower the detection limit in the experimental systems, thus making it possible to monitor the success of TSE pathogen elimination more efficiently. There is a need for research both into the development of detection methods of human-pathogenic TSE in asymptomatic carriers and into therapeutics for the treatment of individuals infected with these pathogens.
